Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection.
Although immunodeficiency is usually considered a prerequisite of oncogenesis, a detailed immune pro- file in cancer has not yet been described. Without such profiling, it is not surprising that there is a vast discrepancy in the responses of cancer patients to immunotherapy. Our results show that the integrity of the immune system deteriorates with cancer progression by displaying a trend toward decreasing levels of functional T cells, including CD4, naïve, and central memory T cells, and an expansion of hyporesponsive populations such as CD28⁻ and CMV-specific T cells. One hundred and one patients constitute the study group for the observational study reported in this paper. Forty-eight patients with newly diagnosed stages III and IV and 53 patients with extensively treated stage IV disease. The costimulatory molecules CD27 and CD28 were downregulated in all patients. Among the proinflammatory cytokines (IL-6, TNF-α, IFN-γ), only IL-6 differed significantly among the groups, increasing as the cancer stage progressed. Plasma IL-7 did not diVer among the participants. The relative deficits of naïve T cells in cancer patients may be associated with the downregulation of IL-7Rα expression rather than changes in the circulating levels of IL-7. The downregulation of IL-7Rα expression was shown to be associated with increased levels of intracellular CMV. The present study suggests that the immune impairment in patients with cancer is associated with multiple factors, such as the stage of cancer, consequence of CMV infection and impact of treatment.
Chen
I-Hsuan
IH
Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan.
Lai
Yuen-Liang
YL
Wu
Chien-Liang
CL
Chang
Yi-Fang
YF
Chu
Chen-Chung
CC
Tsai
I-Fang
IF
Sun
Fang-Ju
FJ
Lu
Yen-Ta
YT
D000368:Aged; D018106:CD28 Antigens / Q000276:immunology; D016516:CD4-CD8 Ratio; D017322:Clinical Trials, Phase II as Topic; D003430:Cross-Sectional Studies; D016207:Cytokines / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000276:immunology*; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000276:immunology*; D007156:Immunologic Memory; D007167:Immunotherapy; D053699:Interleukin-7 Receptor alpha Subunit / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000276:immunology
D018106:CD28 Antigens; D016207:Cytokines; D053699:Interleukin-7 Receptor alpha Subunit; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7
Nature. 1999 Oct 14;401(6754):708-12
10537110
Immunol Rev. 2005 Jun;205:147-57
15882351
Science. 1999 Jan 29;283(5402):680-2
9924026
Immunity. 2007 Oct;27(4):670-84
17950003
Blood. 2005 Sep 15;106(6):2091-8
15947093
J Immunol. 2006 Sep 15;177(6):3960-71
16951359
Immunol Rev. 2006 Jun;211:58-66
16824117
Blood. 2005 Jan 1;105(1):241-50
15345595
J Exp Med. 1990 Mar 1;171(3):801-17
2307933
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
15980149
J Clin Invest. 2005 Jun;115(6):1616-26
15931392
Nature. 2001 Mar 1;410(6824):106-11
11242051
J Exp Med. 2004 Nov 15;200(10):1347-58
15545358
J Clin Invest. 2007 May;117(5):1175-83
17476347
J Immunol. 2002 Aug 15;169(4):1984-92
12165524
Immunol Rev. 2006 Jun;211:214-24
16824130
Clin Microbiol Infect. 2008 Mar;14(3):221-7
18070129
Nat Rev Immunol. 2008 Jul;8(7):512-22
18469829
Immunol Rev. 2006 Jun;211:154-63
16824125
J Immunol. 2011 Jul 1;187(1):7-9
21690331
AIDS. 2005 Nov 18;19(17):1981-6
16260904
Nat Rev Immunol. 2006 May;6(5):383-93
16622476
J Exp Med. 2002 Jun 17;195(12):1523-32
12070280
Immunity. 2004 Aug;21(2):289-302
15308108